John Daly, a director of CareCloud, Inc. (NASDAQ:CCLD), recently sold 5,000 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The health care technology company, which is currently valued at approximately $59 million, has shown exceptional performance with a 141% return over the past year. According to InvestingPro analysis, the stock is trading close to its Fair Value. The transaction, dated December 31, 2024, was executed at a price of $3.87 per share, amounting to a total value of $19,350. Following this sale, Daly continued to own 61,750 shares of the company. InvestingPro subscribers have access to 12 additional key insights about CCLD, including a detailed analysis of its financial health, which is currently rated GREAT with an overall score of 3.16.

In other recent news, healthcare technology provider CareCloud saw a downgrade from Roth/MKM, which moved from a Buy to Neutral rating due to projections for weak growth in 2025. Despite the bag -or cost-cutting measures, the company’s growth outlook remains unimpressive, leading to a reduction in revenue forecasts. This came despite a third-quarter revenue of $28.5 million, which met analyst expectations, and an increase in the company’s adjusted EBITDA of $6.8 million.

CareCloud’s third-quarter earnings report also revealed a slight decline in revenue, down to $28.5 million from $29.3 million last year. However, the company’s adjusted EBITDA saw a significant year-over-year increase to $6.8 million, and free cash flow increased significantly, reaching $10.3 million.

The company fully repaid its line of credit and announced plans to resume dividend payments in March 2025. CareCloud also reported a positive GAAP net income of $3.1 million, from the loss of $2.7 million in Q3 2023. These are the new developments that are shaping the company’s trajectory.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.